A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
10/2002
10/17/2002	US20020151573 Anticancer agents
10/17/2002	US20020151569 Peroxisome Proliferator Activated Receptors (PPARs) antagonists 4-oxo-5-thiazolidine acetamide derivatives
10/17/2002	US20020151560 Coumarin compounds as microtubule stabilizing agents and therapeutic uses thereof
10/17/2002	US20020151558 Triazolo compounds as MMP inhibitors
10/17/2002	US20020151555 Pyrimidine matrix metalloproteinase inhibitors
10/17/2002	US20020151554 Cyclin-dependent kinase inhibitors such as (4-Amino-2-((4-(4-methyl-1-piperazinyl)phenyl)amino)-5-thiazolyl) (2,3-dihydro-1,4-benzodioxin-6-yl)methanone for treatment of breast, lung, colon, and prostate cancer/tumors
10/17/2002	US20020151549 Such as 3-(6-bromo-2-methylimidazo(1,2-a)pyridin-3-yl)-1H-pyrazol-1-yl 2-methyl-5-nitrophenyl sulfone; useful as phosphatidylinositol-3-kinase (PI3K) inhibitors and antitumor agents
10/17/2002	US20020151528 Use of 2alpha-methyl-19-nor-20(S)-1alpha,25-dihydroxyvitamin D3 to increase bone strength
10/17/2002	US20020151525 Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation
10/17/2002	US20020151518 Oligonucleotide mediated specific sytokine induction and reduction of tumor growth in a mammal
10/17/2002	US20020151517 Administering to the mammal nucleosomes(a complex of DNA and histones) that elicit the production of antinuclear autoantibodies sufficient to inhibit neoplastic cell growth
10/17/2002	US20020151516 Carrier:nucleic acids complexes containing nucleic acids encoding anti-angiogenic peptides and their use in gene therapy
10/17/2002	US20020151512 Used to diagnose or treat cancer, restenosis, a disease caused by a virus, a disease affected by integrins or cell-cell adhesion receptor or a disease triggered by diffusible factors
10/17/2002	US20020151511 Antisense oligonucleotide modulation of human MDM2 expression
10/17/2002	US20020151508 Administering therapeutically effective amount of liposomal anthracycline composition in association with therapeutically effective amount of antibody directed against extracellular domain of growth factor receptor
10/17/2002	US20020151505 Treatment of helicobacter with isothiocyanates
10/17/2002	US20020151503 Methods of cancer treatment using naaladase inhibitors
10/17/2002	US20020151498 Medicaments that modify activity of Lipolysis Stimulated Receptor and that can be used to influence partitioning of dietary lipids between liver and peripheral tissues, including adipose tissue
10/17/2002	US20020151497 Inhibitors comprise sequences derived from specific regions of the Lyn-kinase
10/17/2002	US20020151494 Novel amino acid sequences for human semaphorin-like polypeptides
10/17/2002	US20020151493 Therapeutic agents and methods of use thereof for the modulation of angiogenesis
10/17/2002	US20020151488 G-CSF analog compositions and methods
10/17/2002	US20020151487 Method and reagents for epithelial barrier formation and treatment of malignant and benign skin disorders by modulating the notch pathway
10/17/2002	US20020151482 Administering to a bird or mammal a PRG-B polypeptide as an angiogenesis inhibitor; antitumor, -carcinogenic, -neoplastic and -arthritic agents; diabetic retinopathy; cancer of the lung, breast, or prostate gland; gene therapy
10/17/2002	US20020151480 Identifying a compound to treat a cardiovascular disease, e.g., atherosclerosis, characterized by aberrant 10218 nucleic acid activity or expression; detecting the presence of a nucleic acid in the sample that hybridizes to the probe
10/17/2002	US20020151475 Compounds and methods for modulating cell adhesion
10/17/2002	US20020151472 Trefoil factor (TFF) peptides (tricyclic peptides, e.g., TFF2 peptides), for increasing the viscosity of mucus layers; used for treating damaged or abnormal mucus layers, e.g. in the gastrointestinal tract, respiratory/urogential systems, eyes
10/17/2002	US20020151049 Self-enhancing, pharmacologically controllable expression systems
10/17/2002	US20020151022 Kinase capable of site-specific phosphorylation of IkappaBalpha
10/17/2002	US20020151009 Human polynucleotides, polypeptides, and antibodies
10/17/2002	US20020150986 Extracellular matrix signalling molecules
10/17/2002	US20020150984 Peptides for activation and inhibition of deltaPKC
10/17/2002	US20020150977 Nucleotide sequences coding protein for use in the diagnosis, treatment and prevention of autoimmune, cell proliferative and inflammatory diseases
10/17/2002	US20020150975 Peptide for use the treatment of cancer
10/17/2002	US20020150954 Detecting modulators of tumor suppressor gene activity; obtain cells, incubate with modulator, detec adjustment of gene expression from tumor suppressor gene, adjustment in activity indicates modulator
10/17/2002	US20020150638 Solid form compositions containing an extract of a raw material as the active ingredient and process of preparing the same
10/17/2002	US20020150624 Mixture of drug, aminoacrylate polymer and acid
10/17/2002	US20020150574 Cancer diagnosis, therapy; Dna vaccine
10/17/2002	US20020150552 Compositions comprising mixtures of therapeutic proteins and methods of producing the same
10/17/2002	US20020150541 Mixture of human interferons; viricides; anticancer agents; antiinflammatory agents;
10/17/2002	DE10164711A1 Verwendung von Zuckerphosphaten, Zuckerphosphatanalogen, Aminosäuren und/oder Aminosäureanalogen zur Modulation des Glycolyse-Enzym-Komplexes, des Malat Aspartat Shuttles und/oder der Transaminasen Use of sugar phosphates, sugar phosphate analogs, amino acids and / or amino acid analogs to modulate the glycolytic enzyme complex, the malate aspartate shuttle and / or the transaminases
10/17/2002	DE10118550A1 New 3-ethanoylamino-3-phenyl-propionic acid derivatives, are integrin agonists or antagonists useful e.g. for treating angiogenic, cardiovascular, inflammatory, osteolytic or tumor diseases or infections
10/17/2002	DE10117728A1 Pharmazeutische Formulierungen für Xanthogenate Pharmaceutical formulations for xanthates
10/17/2002	DE10116527A1 Tumorhemmende Galliumverbindungen Tumor-inhibiting gallium
10/17/2002	CA2762966A1 Hsa-free formulations of interferon-beta
10/17/2002	CA2699611A1 Desaturase genes and uses thereof
10/17/2002	CA2698579A1 Desaturase genes and uses thereof
10/17/2002	CA2446462A1 Chimeric vaccines
10/17/2002	CA2443694A1 Anti-cd19 immunotoxins
10/17/2002	CA2443405A1 Use of cd25 binding molecules in steroid-resistant patients
10/17/2002	CA2443378A1 Methods of screening and using inhibitors of angiogenesis
10/17/2002	CA2443372A1 Immunotherapeutic combinations for the treatment of tumors that over-express gangliosides
10/17/2002	CA2443334A1 Protein modification and maintenance molecules
10/17/2002	CA2443293A1 Production of polyclonal monospecific antibodies against upar variants del4, del5 and del4+5, and the use thereof for diagnostic and therapeutical purposes
10/17/2002	CA2443207A1 Process for producing trunkamide a compounds
10/17/2002	CA2443085A1 Somatostatin agonists
10/17/2002	CA2443040A1 Solid pharmaceutical composition comprising 4 -cyano-trifluoro-3-(4-fluorophenyl-sulphonyl) -2-hydroxy-2-methylpropiono- m toluidide and pvp
10/17/2002	CA2443025A1 Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
10/17/2002	CA2442991A1 Compositions and methods for the prevention and treatment of human prostate cancer
10/17/2002	CA2442957A1 Renal cell carcinoma tumor markers
10/17/2002	CA2442863A1 Tumour inhibiting gallium compounds
10/17/2002	CA2442849A1 Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil
10/17/2002	CA2442739A1 Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
10/17/2002	CA2442695A1 Indolinones substituted in the 6-position, the preparation thereof and their use as medicaments
10/17/2002	CA2442605A1 Compounds and methods for inhibiting mrp1
10/17/2002	CA2442530A1 Compounds and methods for inhibiting mrp1
10/17/2002	CA2442386A1 Epitope sequences
10/17/2002	CA2442141A1 Compounds and pharmaceutical compositions for inhibiting mrp1
10/17/2002	CA2442092A1 Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication
10/17/2002	CA2441941A1 Thiazolidinediones alone or in combination with other therapeutic agents for inhibiting or reducing tumour growth
10/17/2002	CA2441538A1 Stimulation of osteogenesis using rank ligand fusion proteins
10/17/2002	CA2441499A1 Method for producing a vaccine
10/17/2002	CA2441442A1 Conjugate of hydroxyalkyl starch and an active agent
10/17/2002	CA2440724A1 Pyrazolopyrimidines as therapeutic agents
10/17/2002	CA2439503A1 Recombination super compound interferon used as hepatitis b surface antigen and e antigen inhibitor
10/17/2002	CA2439111A1 Mucosal boosting following parenteral priming
10/17/2002	CA2429376A1 Mitogenic oxygenase regulators
10/16/2002	WO2001079186A1 2-guanidino-4-arylchinazolines as nhe-3 inhibitors
10/16/2002	EP1249451A2 Bicyclic-substituted 4-amino-pyridopyrimidine derivatives
10/16/2002	EP1249246A1 Use of an histone deacetylase inhibitor for the treatment of diseases associated with an hpv infection
10/16/2002	EP1249236A1 ANTICANCER AGENTS, PERFUMES OR FOODS AND DRINKS CONTAINING $g(v)-HYDROXYFATTY ACIDS
10/16/2002	EP1248858A1 Antisense modulation of caspase 8 expression
10/16/2002	EP1248847A1 Irak-4: compositions and methods of use
10/16/2002	EP1248842A1 2871 receptor, a g-protein coupled receptor and methods of use thereof
10/16/2002	EP1248841A2 Genes differentially expressed in breast cancer
10/16/2002	EP1248836A2 Hybrid cells obtainable from antigen presenting cells
10/16/2002	EP1248835A2 Genetically modified fibroblast cell
10/16/2002	EP1248801A1 Human polynucleotides, polypeptides, and antibodies
10/16/2002	EP1248795A1 Antisense modulation of macrophage migration inhibitory factor expression
10/16/2002	EP1248794A1 Antisense modulation of smad7 expression
10/16/2002	EP1248793A1 Polynucleotides for inhibiting metastasis and tumor cell growth
10/16/2002	EP1248792A1 Antisense modulation of peroxisome proliferator-activated receptor gamma expression
10/16/2002	EP1248787A2 Novel subtituted pyrazolo[4, 3-e]diazepines, pharmaceutical compositions containing them, use as medicinal products and processes for preparing them
10/16/2002	EP1248785A1 Novel tetrahydropyridines, preparation method and pharmaceutical compositions containing same
10/16/2002	EP1248782A1 Anticancer compound and enantiomer separation method useful for synthesizing said compound
10/16/2002	EP1248781A1 Pyrazole cyclic amp-specific pde inhibitors
10/16/2002	EP1248779A2 Glycosidase ihhibitors and preparation thereof
10/16/2002	EP1248776A1 Semi-synthetic taxanes with antitumor and antiangiogenetic activities
10/16/2002	EP1248774A2 Polyhydroxystilbenes and stilbene oxides as antipsoriatic agents and protein kinase inhibitors
10/16/2002	EP1248761A1 Compounds which mimic the chemical and biological properties of discodermolide

1 ... 1651 1652 1653 1654 1655 1656 1657 1658 1659 1660 1661 1662 1663 1664 1665 1666 1667 1668 1669 1670 1671 ... 2211